GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowheadnews2021-11-22T15:49:51+00:00November 22nd, 2021|FierceBiotech|
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targetsnews2021-11-22T13:57:51+00:00November 22nd, 2021|FierceBiotech|
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded dealnews2021-11-22T13:33:39+00:00November 22nd, 2021|FierceBiotech|
Sanifit, having put Spain’s biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 datanews2021-11-22T11:11:15+00:00November 22nd, 2021|FierceBiotech|
Twist nabs antibody discovery biotech Abveris for $190M a week after spinning out COVID unitnews2021-11-22T10:59:10+00:00November 22nd, 2021|FierceBiotech|
Connect Biopharma touts positive results for Dupixent rival, but shares halved as investors await hard datanews2021-11-22T09:40:36+00:00November 22nd, 2021|FierceBiotech|
‘What it takes’: As Lilly’s Alzheimer’s drug approaches FDA, launch leader feels ‘amplified’ sense of excitementnews2021-11-19T17:44:19+00:00November 19th, 2021|FierceBiotech|
‘What it takes’: Beyond the headlines, women are pushing groundbreaking new Alzheimer’s treatments forwardnews2021-11-19T16:53:40+00:00November 19th, 2021|FierceBiotech|
New insights into how cancer cripples immune cells could fuel fresh I-O approachesnews2021-11-19T14:30:15+00:00November 19th, 2021|FierceBiotech|
Enanta dumps oral hep B program after safety warnings in early testnews2021-11-19T13:13:59+00:00November 19th, 2021|FierceBiotech|
